Literature DB >> 21296615

Definition and classification of cancer cachexia: an international consensus.

Kenneth Fearon1, Florian Strasser, Stefan D Anker, Ingvar Bosaeus, Eduardo Bruera, Robin L Fainsinger, Aminah Jatoi, Charles Loprinzi, Neil MacDonald, Giovanni Mantovani, Mellar Davis, Maurizio Muscaritoli, Faith Ottery, Lukas Radbruch, Paula Ravasco, Declan Walsh, Andrew Wilcock, Stein Kaasa, Vickie E Baracos.   

Abstract

To develop a framework for the definition and classification of cancer cachexia a panel of experts participated in a formal consensus process, including focus groups and two Delphi rounds. Cancer cachexia was defined as a multifactorial syndrome defined by an ongoing loss of skeletal muscle mass (with or without loss of fat mass) that cannot be fully reversed by conventional nutritional support and leads to progressive functional impairment. Its pathophysiology is characterised by a negative protein and energy balance driven by a variable combination of reduced food intake and abnormal metabolism. The agreed diagnostic criterion for cachexia was weight loss greater than 5%, or weight loss greater than 2% in individuals already showing depletion according to current bodyweight and height (body-mass index [BMI] <20 kg/m(2)) or skeletal muscle mass (sarcopenia). An agreement was made that the cachexia syndrome can develop progressively through various stages--precachexia to cachexia to refractory cachexia. Severity can be classified according to degree of depletion of energy stores and body protein (BMI) in combination with degree of ongoing weight loss. Assessment for classification and clinical management should include the following domains: anorexia or reduced food intake, catabolic drive, muscle mass and strength, functional and psychosocial impairment. Consensus exists on a framework for the definition and classification of cancer cachexia. After validation, this should aid clinical trial design, development of practice guidelines, and, eventually, routine clinical management.
Copyright © 2011 Elsevier Ltd. All rights reserved.

Entities:  

Mesh:

Year:  2011        PMID: 21296615     DOI: 10.1016/S1470-2045(10)70218-7

Source DB:  PubMed          Journal:  Lancet Oncol        ISSN: 1470-2045            Impact factor:   41.316


  1347 in total

1.  JAK/STAT3 pathway inhibition blocks skeletal muscle wasting downstream of IL-6 and in experimental cancer cachexia.

Authors:  Andrea Bonetto; Tufan Aydogdu; Xiaoling Jin; Zongxiu Zhang; Rui Zhan; Leopold Puzis; Leonidas G Koniaris; Teresa A Zimmers
Journal:  Am J Physiol Endocrinol Metab       Date:  2012-06-05       Impact factor: 4.310

2.  Development of a lack of appetite item bank for computer-adaptive testing (CAT).

Authors:  Lise Holst Thamsborg; Morten Aa Petersen; Neil K Aaronson; Wei-Chu Chie; Anna Costantini; Bernhard Holzner; Irma M Verdonck-de Leeuw; Teresa Young; Mogens Groenvold
Journal:  Support Care Cancer       Date:  2014-11-14       Impact factor: 3.603

3.  Insulin supplementation attenuates cancer-induced cardiomyopathy and slows tumor disease progression.

Authors:  James T Thackeray; Stefan Pietzsch; Britta Stapel; Melanie Ricke-Hoch; Chun-Wei Lee; Jens P Bankstahl; Michaela Scherr; Jörg Heineke; Gesine Scharf; Arash Haghikia; Frank M Bengel; Denise Hilfiker-Kleiner
Journal:  JCI Insight       Date:  2017-05-18

4.  An AMP-activated protein kinase-stabilizing peptide ameliorates adipose tissue wasting in cancer cachexia in mice.

Authors:  Maria Rohm; Michaela Schäfer; Victor Laurent; Bilgen Ekim Üstünel; Katharina Niopek; Carolyn Algire; Oksana Hautzinger; Tjeerd P Sijmonsma; Annika Zota; Dasa Medrikova; Natalia S Pellegata; Mikael Ryden; Agné Kulyte; Ingrid Dahlman; Peter Arner; Natasa Petrovic; Barbara Cannon; Ez-Zoubir Amri; Bruce E Kemp; Gregory R Steinberg; Petra Janovska; Jan Kopecky; Christian Wolfrum; Matthias Blüher; Mauricio Berriel Diaz; Stephan Herzig
Journal:  Nat Med       Date:  2016-08-29       Impact factor: 53.440

5.  Formation of colorectal liver metastases induces musculoskeletal and metabolic abnormalities consistent with exacerbated cachexia.

Authors:  Joshua R Huot; Leah J Novinger; Fabrizio Pin; Ashok Narasimhan; Teresa A Zimmers; Thomas M O'Connell; Andrea Bonetto
Journal:  JCI Insight       Date:  2020-05-07

6.  Hypercaloric enteral nutrition in patients with amyotrophic lateral sclerosis: a randomised, double-blind, placebo-controlled phase 2 trial.

Authors:  Anne-Marie Wills; Jane Hubbard; Eric A Macklin; Jonathan Glass; Rup Tandan; Ericka P Simpson; Benjamin Brooks; Deborah Gelinas; Hiroshi Mitsumoto; Tahseen Mozaffar; Gregory P Hanes; Shafeeq S Ladha; Terry Heiman-Patterson; Jonathan Katz; Jau-Shin Lou; Katy Mahoney; Daniela Grasso; Robert Lawson; Hong Yu; Merit Cudkowicz
Journal:  Lancet       Date:  2014-02-28       Impact factor: 79.321

7.  Decreased Skeletal Muscle Volume Is a Predictive Factor for Poorer Survival in Patients Undergoing Surgical Resection for Pancreatic Ductal Adenocarcinoma.

Authors:  Motokazu Sugimoto; Michael B Farnell; David M Nagorney; Michael L Kendrick; Mark J Truty; Rory L Smoot; Suresh T Chari; Michael R Moynagh; Gloria M Petersen; Rickey E Carter; Naoki Takahashi
Journal:  J Gastrointest Surg       Date:  2018-02-01       Impact factor: 3.452

8.  [A case report of the difficulty treating an endstage oncologic ENT patient with parenteral nutrition].

Authors:  Ulrike Uxa-Benold; Ralph Simanek; Annette Henry; Dietmar Weixler; Klaus Geissler
Journal:  Wien Med Wochenschr       Date:  2014-04-29

9.  Skeletal Muscle Metrics on Clinical 18F-FDG PET/CT Predict Health Outcomes in Patients with Sarcoma.

Authors:  Brent Foster; Robert D Boutin; Leon Lenchik; David Gedeon; Yu Liu; Vinay Nittur; Ramsey D Badawi; Chin-Shang Li; Robert J Canter; Abhijit J Chaudhari
Journal:  J Nat Sci       Date:  2018

10.  Interplay of adipokines and myokines in cancer pathophysiology: Emerging therapeutic implications.

Authors:  Maria Dalamaga
Journal:  World J Exp Med       Date:  2013-08-20
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.